公开(公告)号：EP3137106A1

公开(公告)日：2017-03-08

申请号：EP15786133.7

申请日：2015-05-01

申请人： Sanaria Inc.

发明人： EAPPEN, Abraham G. ,  HOFFMAN, Stephen L.

IPC分类号： A61K39/015

CPC分类号： A61K39/015 ,  A61K2039/52 ,  A61K2039/522 ,  C12N1/10 ,  Y02A50/412

摘要： The application is directed to in-vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.

摘要翻译： 本申请涉及人类宿主范围的体外培养的疟原虫子孢子及其制备方法，其中从配子母细胞阶段到孢子体阶段的孢子体在蚊子外部。 本文提供了人体宿主范围的体外培养的感染性疟原虫子孢子（SPZ），特别是恶性疟原虫，间日疟原虫，卵形疟原虫，疟疾和疟原虫，其中从配子母细胞阶段到子孢子阶段的孢子体是外部的 蚊子及其制造方法。

公开(公告)号：EP3039421A2

公开(公告)日：2016-07-06

申请号：EP14839238.4

申请日：2014-09-02

申请人： Sanaria Inc. ,  Antigen Discovery Inc. ,  The United States of America, represented by the Secretary, Department of Health and Human Services

发明人： FELGNER, Philip ,  HOFFMAN, Stephen L. ,  SEDER, Robert

IPC分类号： G01N33/00 ,  G01N33/569

CPC分类号： G01N33/6854 ,  A61K39/015 ,  G01N2333/445 ,  G01N2469/20 ,  Y02A50/412 ,  Y02A50/58

摘要： Disclosed herein are diagnostic assays for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The assays comprise the use of proteomes representing at least 50% of Pf, preferably coupled to a solid phase as a fixed array. The arrays are used to probe the sera of human subjects, particularly subjects of human clinical trials of whole parasite malaria vaccines as well as public health vaccination campaigns. Serum samples with antibody profiles most strongly reactive in multiplex to CSP and MSP5 demonstrate a sensitivity of from 92% to 100% and a specificity of from 84% to 89%.

摘要翻译： 在诊断分析公开了一种用于识别个人的价值也受到保护，不引起恶性疟。 搜索分析是确定性的开采不仅Pf的全寄生虫疫苗的个体对象的保护效果特别有用，所以但接种对象的群体中。 该试验包括表示Pf的至少50％的使用蛋白质组的，优选偶联于固相作为固定阵列。 这些阵列是用于测试人的主体，整个寄生虫疟疾疫苗的人体临床试验以及公共卫生疫苗接种活动的特别对象的血清。 与抗体谱中复用最强烈的反应性，以CSP和MSP5血清样品表明的从92％至100％的灵敏度和84％的从至89％的特异性。